Home Categories Send inquiry

2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0 Purity ≥99.5% (GC) Sitagliptin Phosphate Monohydrate Intermediate

Supply Sitagliptin Phosphate Monohydrate Related Intermediates: Sitagliptin API CAS 486460-32-6 Sitagliptin Phosphate Monohydrate API CAS 654671-77-9 2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0 Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8 Sitagliptin Triazole Hydrochloride CAS 762240-92-6 Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3
Chemical Name 2,4,5-Trifluorophenylacetic Acid
CAS Number 209995-38-0
CAT Number RF-PI1191
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C8H5F3O2
Molecular Weight 190.12
Melting Point 121.0 to 125.0℃
Solubility Soluble in Methanol
Brand Ruifu Chemical
Item Specifications
Appearance White to Off-White Powder
Purity / Analysis Method ≥99.5% (GC)
Moisture (K.F) ≤0.50%
Residue on Igniton ≤0.50%
Total Impurities ≤0.50%
Test Standard Enterprise Standard
Usage Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9)
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture. 2,4,5-Trifluorophenylacetic Acid (CAS: 209995-38-0) is an intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9). Sitagliptin Phosphate (STG) is used to treat DM type 2 because it improves glycemic control by increasing the levels of active incretin hormones, GLP-1 (peptide-1) and GIP (glucose-dependent insulinotropic peptide). The activation of these incretins in β-pancreatic cells causes increased levels of cyclic adenosine monophosphate (cAMP) and intracellular calcium, with subsequent glucose-dependent insulin secretion (2). This hypoglycemic drug belongs to a new class called dipeptidyl peptidase IV inhibitors. STG was approved by the FDA in 2006.